Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Expression of Progesterone and Androgen Receptors in the Breast of Premenopausal Women, Considering Menstrual Phase.

Fahlén M, Zhang H, Löfgren L, Masironi B, VON Schoultz E, VON Schoultz BO, Sahlin L.

Anticancer Res. 2018 Mar;38(3):1499-1510.

PMID:
29491078
2.

Expression of cyclooxygenase-1 and cyclooxygenase-2, syndecan-1 and connective tissue growth factor in benign and malignant breast tissue from premenopausal women.

Fahlén M, Zhang H, Löfgren L, Masironi B, von Schoultz E, von Schoultz B, Sahlin L.

Gynecol Endocrinol. 2017 May;33(5):353-358. doi: 10.1080/09513590.2016.1260109. Epub 2017 Feb 21.

PMID:
28277128
3.

Expression of Estrogen Receptors in Relation to Hormone Levels and the Nottingham Prognostic Index.

Fahlén M, Zhang H, Löfgren L, Masironi B, VON Schoultz E, VON Schoultz BO, Sahlin L.

Anticancer Res. 2016 Jun;36(6):2839-47.

PMID:
27272795
4.

Megestrol acetate may stimulate the production of insulin-like growth factor 1 in breast tissues of women with breast cancer.

Fahlén M, Löfgren L, von Schoultz E, Naessén S, Carlström K, Söderqvist G.

Horm Mol Biol Clin Investig. 2013 Jun;13(3):51-4. doi: 10.1515/hmbci-2013-0004.

PMID:
25436713
5.

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.

Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E.

Eur J Cancer. 2013 Jan;49(1):52-9. doi: 10.1016/j.ejca.2012.07.003. Epub 2012 Aug 11.

PMID:
22892060
6.

Health-related quality of life during hormone therapy after breast cancer: a randomized trial.

Fahlén M, Wallberg B, von Schoultz E, Carlström K, Svensson G, Wilking N, Brandberg Y.

Climacteric. 2011 Feb;14(1):164-70. doi: 10.3109/13697131003660593. Epub 2010 Mar 2.

PMID:
20196640
7.

Hormone replacement therapy after breast cancer: attitudes of women eligible in a randomized trial.

Wallberg B, von Schoultz E, Bolund C, Bergh J, Wilking N.

Climacteric. 2009 Dec;12(6):478-89. doi: 10.3109/13697130902912597.

PMID:
19905900
8.

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.

Med Oncol. 2009 Dec;26(4):480-90. doi: 10.1007/s12032-008-9157-9. Epub 2009 Jan 7.

PMID:
19130322
9.

Associations between serum testosterone levels, cell proliferation and progesterone receptor content in normal and malignant breast tissue in postmenopausal women.

Hofling M, Löfgren L, von Schoultz E, Carlström K, Söderqvist G.

Gynecol Endocrinol. 2008 Jul;24(7):405-10. doi: 10.1080/09513590802193061.

PMID:
18645713
10.

Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women.

Lofgren L, Sahlin L, Jiang S, Von Schoultz B, Fernstad R, Skoog L, Von Schoultz E.

Anticancer Res. 2007 Sep-Oct;27(5A):3045-50.

11.

Hormone therapy and estrogen receptor expression in breast cancer.

Friman EI, Mahlman M, Nilsson B, Skoog L, Löfgren L, Wilking N, Von Schoultz E.

Acta Oncol. 2007;46(2):194-8.

PMID:
17453368
12.

Are estrogen receptor content in breast cancer and effects of tamoxifen on sex hormone-binding globulin markers for individual estrogen sensitivity?

Löfgren L, von Schoultz E, Fernstad R, von Schoultz B, Carlström K.

J Steroid Biochem Mol Biol. 2006 Apr;99(1):76-9. Epub 2006 Apr 18.

PMID:
16621526
13.

Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study.

Lundström E, Söderqvist G, Svane G, Azavedo E, Olovsson M, Skoog L, von Schoultz E, von Schoultz B.

Fertil Steril. 2006 Apr;85(4):989-95.

PMID:
16580385
14.
15.

Expression of sex steroid receptor subtypes in normal and malignant breast tissue - a pilot study in postmenopausal women.

Löfgren L, Sahlin L, Von Schoultz B, Fernstad R, Skoog L, Von Schoultz E.

Acta Oncol. 2006;45(1):54-60.

PMID:
16464796
16.

Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.

von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group.

J Natl Cancer Inst. 2005 Apr 6;97(7):533-5.

PMID:
15812079
17.

Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.

Löfgren L, Wallberg B, Wilking N, Fornander T, Rutqvist LE, Carlström K, von Schoultz B, von Schoultz E.

Med Oncol. 2004;21(4):309-18.

PMID:
15579914
18.

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.

Sverrisdóttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE.

J Clin Oncol. 2004 Sep 15;22(18):3694-9.

PMID:
15365065
19.
20.

[A unique cooperation between trials on hormone replacement therapy following breast cancer].

Holmberg L, von Schoultz E, Mattsson LA.

Lakartidningen. 2003 Jun 26;100(26-27):2317. Swedish. No abstract available.

PMID:
12872385

Supplemental Content

Loading ...
Support Center